

November 11, 2025

Limited rebate program for Tresiba® and Fiasp®

Novo Nordisk has informed us that they will be **reducing the WAC price for Tresiba and Fiasp effective January 1, 2026.**

To support customers during this transition, we are pleased to share that Novo Nordisk will be offering a one-time limited rebate program for eligible purchases made between December 8 and December 17, 2025.

Limited rebate program details:

Eligible purchases	<ul style="list-style-type: none">• Purchases made at WAC and between December 8 – December 17, 2025 will be eligible for the limited rebate program. Purchase date is defined as order date. 340B and contracted price purchases will not be eligible.• Eligibility will also be based on trade classification and includes: Retail Long Term Care Mail Order Pharmacy
Rebate	<ul style="list-style-type: none">• Novo Nordisk will review purchases to determine the credit amount.• The credit amount will be calculated as: 96% of the WAC price differential between current WAC and price from January 1, 2026.
Credit issuance	<ul style="list-style-type: none">• Credits will be issued to eligible customers via AmerisourceBergen.• The credits will be issued in a timely manner. Timing may vary depending on the completion of each step, including verification of eligibility, calculation of purchases and processing.

Eligible items:

For the full list of eligible items and other details, please [review the full Novo Nordisk announcement here](#).

Planning your returns:

If you have inventory to return, you should begin the return process now. Ensure your return request is submitted and product is physically returned to your AmerisourceBergen distribution center **before December 1**. AmerisourceBergen **will not accept returns of these products December 1 through January 2, 2026**. Product returned after January 2, regardless of when purchased, will be credited at the lower price.

If you have any questions about this announcement, please reach out to your AmerisourceBergen account representative.

Thank you for your attention to this message and for your continued partnership in healthcare.